Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2
Latest Information Update: 08 May 2023
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Dolutegravir/lamivudine/tenofovir; Tenofovir dipivoxil fumarate
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms AVERTAS-2
- 28 Apr 2023 This trial has been discontinued (End Date: 20 Apr 2023), according to European Clinical Trials Database record.
- 13 Jul 2020 New trial record